メニュー
Track pharmaceutical M&A, licensing, and investment deals. Use for competitive intelligence, market analysis, and identifying partnership opportunities. Keywords: deals, M&A, licensing, partnership, collaboration, acquisition, pharma deals
Codex または Claude でインストール この Prompt をコピーして Codex、Claude、または他のアシスタントに貼り付けると、Skill ページを確認してインストールできます。
SOC 職業分類に基づく
Global drug development pipeline tracking by disease, target, mechanism, or company. Use for competitive intelligence, opportunity identification, and trend analysis. Keywords: pipeline, drug development, clinical trials, R&D tracking, competitive landscape
Structure-based similarity search and scaffold analysis for drug discovery. Use for lead hopping, scaffold morphing, and chemical space exploration. Keywords: similarity search, scaffold hopping, chemical space, fingerprint, Tanimoto
Analyze target competitive landscape including existing drugs, pipeline companies, differentiation opportunities, and market maturity assessment. Keywords: target competition, landscape, differentiation, pipeline analysis, market share
Target safety assessment including known toxicities, essentiality, and off-target concerns. Use for early safety risk evaluation and target selection. Keywords: target safety, toxicity, essential gene, knockout, safety risks
Comprehensive target validation assessing druggability, disease association strength, tractability, and competitive landscape. Use for go/no-go decisions on target selection. Keywords: target validation, druggability, tractability, disease association, genetic validation
ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) prediction for drug candidates. Use for assessing drug-likeness, PK properties, and safety risks early in drug discovery. Keywords: ADMET, PK, toxicity, drug-likeness, DILI, hERG, bioavailability
| name | deal-tracker |
| description | Track pharmaceutical M&A, licensing, and investment deals. Use for competitive intelligence, market analysis, and identifying partnership opportunities. Keywords: deals, M&A, licensing, partnership, collaboration, acquisition, pharma deals |
| category | Business Intelligence |
| tags | ["deals","manda","licensing","partnership","investment"] |
| version | 1.0.0 |
| author | Drug Discovery Team |
| dependencies | ["sec-filings","press-releases","deal-databases"] |
Track pharmaceutical industry deals, M&A, and partnerships.
/deals --oncology --year 2024
/partnership --type licensing --target "EGFR"
/ma-summary --biotech --threshold 100M
| Section | Description | Source |
|---|---|---|
| Deal Feed | Recent announcements | Press releases, SEC |
| M&A Tracker | Acquisitions and mergers | SEC 8-K, 10-K |
| Licensing Deals | In-licensing, out-licensing | Company announcements |
| Partnerships | R&D collaborations | Press releases |
| Investment | Venture capital, IPO | SEC, exchanges |
# Deal Tracker: Oncology Targets (2024)
## Summary
| Metric | Count | Total Value |
|--------|-------|-------------|
| Total Deals | 127 | $45.2B |
| M&A | 12 | $28.5B |
| Licensing | 89 | $14.3B |
| Partnerships | 26 | $2.4B |
## Recent Deals (Last 30 Days)
### M&A
| Date | Acquirer | Target | Value | Type |
|------|----------|--------|-------|------|
| 2024-12-15 | Pfizer | Seagen | $43B | Acquisition |
| 2024-12-10 | BMS | Mirati | $4.8B | Acquisition |
### Licensing
| Date | Licensee | Licensor | Asset | Upfront | Milestones |
|------|----------|---------|-------|---------|------------|
| 2024-12-08 | AstraZeneca | Hengrui | KRAS G12D | $100M | $800M |
| 2024-12-05 | Merck | Daiichi Sankyo | ADC platform | $300M | $1.5B |
## By Target Class
| Target | Deals | Total Value | Avg Upfront |
|--------|-------|-------------|-------------|
| EGFR | 8 | $1.2B | $85M |
| KRAS | 12 | $2.8B | $120M |
| HER2 | 6 | $950M | $78M |
## By Deal Type
| Type | Count | Total Value | Trend |
|------|-------|-------------|-------|
| Acquisition | 12 | $28.5B | ↑ |
| Asset purchase | 45 | $8.2B | → |
| Platform license | 28 | $5.1B | ↑ |
| Co-development | 18 | $1.8B | → |
| Option agreement | 24 | $2.1B | ↓ |
## Key Observations
1. **M&A resurgence**: 12 biotech acquisitions in H2
2. **ADC momentum**: Antibody-drug conjugates dominate
3. **Early-stage focus**: 60% of deals at preclinical/Phase 1
4. **Oncology dominance**: 70% of deal value in oncology
| Type | Description | Typical Structure |
|---|---|---|
| Acquisition | Full company buyout | Cash + stock |
| Asset Purchase | Specific asset(s) | Upfront + milestones |
| Licensing | Rights to develop/sell | Upfront + royalties + milestones |
| Co-development | Joint development | Cost/revenue sharing |
| Collaboration | R&D partnership | Funded research |
| Option | Right to acquire later | Option fee + exercise price |
| Spin-off | Company separation | Share distribution |
| Stage | Typical Upfront | Total Deal |
|---|---|---|
| Preclinical | $10-50M | $100-500M |
| Phase 1 | $30-100M | $200-800M |
| Phase 2 | $50-200M | $500M-2B |
| Phase 3 | $100-500M | $1B-5B |
| Approved | $200M-2B | $2B-10B+ |
# Recent deals feed
python scripts/deal_tracker.py --feed --days 30
# Filter by target
python scripts/deal_tracker.py --target EGFR --include licensing,manda
# Deal summary
python scripts/deal_tracker.py --summary --year 2024 --oncology
# Export to CSV
python scripts/deal_tracker.py --export --format csv --output deals.csv
pip install requests beautifulsoup4 pandas
| Pitfall | Solution |
|---|---|
| Misreported values | Check SEC filings |
| Confusing announced vs closed | Track closing conditions |
| Ignoring milestones | Total value often optimistic |
| Currency confusion | Note USD vs local |
| Double counting | Verify unique deals |